Unified agenda
This article was originally published in The Tan Sheet
Executive Summary
FDA will announce a Notice of Proposed Rulemaking in June on "the use of stimulant active ingredients to relieve symptoms associated with a hangover" in OTC products, the agency announces in HHS' semi-annual "unified agenda." The document, which was published in the Federal Register April 24, also notes that final action is slated for December on a proposal to require additional warnings for OTC bronchodilators containing ephedrine or epinephrine. The proposed amendment was issued by FDA in July (1"The Tan Sheet" July 18, 2005, p. 10). FDA also expects to take final action in August on a proposed rule to allow new indications for bismuth subsalicylate products. The proposal was announced in January 2005 (2"The Tan Sheet" Jan. 10, 2005, p. 7)...
You may also be interested in...
OTC Bronchodilators With Ephedrine Permitted In New Proposed Rule
Additional warnings and other revised labeling would be required for bronchodilator products containing ephedrine or epinephrine under an FDA proposed rule published in the July 13 Federal Register
Overindulgence TFM Gets Bloated With Belching, Gas Indications
FDA will allow for the inclusion of two new indications for bismuth subsalicylate products, according to a proposed amendment to the overindulgence Tentative Final Monograph in the Jan. 5 Federal Register
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.